Ownership of this website has been transferred from Northwestern University to Michigan State University. Please note that some site information may be inaccurate while adjustments to reflect this organizational change are made.
Dr. Sana Salih and colleagues have published a new paper, Dexrazoxane Diminishes Doxorubicin-Induced Acute Ovarian Damage and Preserves Ovarian Function and Fecundity in Mice, on fertility preservation in young mice treated with chemotherapies. Teresa Woodruff says that ‘fertoprotective therapies are the most important next step in research to protect ovarian function in women with cancer.’ Dr. Salih said that the most important points in the paper include ‘The fertoprotective drug, dexrazoxane (Dexra) pre-administration prevented ovarian damage and preserved fertility in pre-pubescent mice treated with doxorubicin (DXR) chemotherapy. Mice treated with Dexra also gave birth to healthier litters, with more pups and larger birth weights than those receiving chemotherapy only. Intriguingly, Dexra also prolonged mice survival following chemotherapy treatment (only 25 % of pre-pubescent mice treated with DXR chemotherapy survived to 8 months while all mice treated with Dexra survived). These high mouse survival rates, ovarian protection and birthing successes were achieved using a dose of Dexra 10 times lower than what is used for adult human cardiac protection.’ Read more at http://news.wisc.edu/24163. The paper can be found here: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0142588
The contents of the Oncofertility Consortium Blog are for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.